A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

Overview

The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 2020

Interventions

  • Drug: K-161
    • K-161 alternate dosage
  • Other: Placebo (Vehicle)
    • Placebo solution

Arms, Groups and Cohorts

  • Experimental: Group 1
    • K-161 Ophthalmic Solution Dose A.
  • Experimental: Group 2
    • K-161 Ophthalmic Solution Dose B.
  • Experimental: Group 3
    • K-161 Ophthalmic Solution Dose C.
  • Placebo Comparator: Group 4
    • Vehicle Solution Dose.

Clinical Trial Outcome Measures

Primary Measures

  • Change in Inferior Corneal Staining
    • Time Frame: 29 Days
    • K-161 compared to Vehicle
  • Change in Ocular Discomfort
    • Time Frame: 29 Days
    • Questionnaire

Secondary Measures

  • Change in Schirmer’s Test value
    • Time Frame: 29 Days
  • Change in Tear Film break-up Time (TFBUT)
    • Time Frame: 29 Days
  • Number of Participants with Treatment Emergent Adverse Events
    • Time Frame: 29 Days

Participating in This Clinical Trial

Inclusion Criteria

  • Be at least 18 years of age at the time of informed consent visit.
  • Have a reported history of dry eye disease in both eyes and a history of eye drop use for dry eye symptoms.
  • Meet all inclusion criteria outlined in the clinical study protocol.

Exclusion Criteria

  • Have any clinically significant ocular condition.
  • Have a history of corneal refractive surgery and/or any other ocular surgical procedure within 12 months.
  • Must not meet any other exclusion criteria outlined in the clinical study protocol.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kowa Research Institute, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Director, Clinical Operations, 919-433-1621, StudyRecruitment@KowaUS.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.